查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1473809

支原体测试市场 - 按产品类型（仪器、试剂盒和试剂、服务）、按技术（PCR、ELISA、微生物培养技术、酶法）、按应用（细胞株测试、病毒测试）、按最终用途和预测， 2024 - 2032

Mycoplasma Testing Market - By Product Type (Instruments, Kits & Reagents, Services), By Technique (PCR, ELISA, Microbial Culturing Techniques, Enzymatic Methods), By Application (Cell Line Testing, Virus Testing), By End-use & Forecast, 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 205 Pages | 商品交期: 2-3个工作天内

价格
简介目录

由于细胞培养研究中支原体污染的流行以及对生物製药和疫苗的强烈需求，支原体测试市场规模预计在 2024 年至 2032 年期间将以超过 11.9% 的复合年增长率增长。对生物製药和疫苗不断增长的需求是推动市场扩张的重要驱动力。生物製药，包括单株抗体、重组蛋白和基因疗法，正成为现代医学的基石。根据世界卫生组织统计，光是2021年，全球疫苗供应量就达160亿剂，价值约1,410亿美元。

由于生物製药和疫苗是使用复杂的细胞培养过程製造的，因此确保其安全性和有效性变得至关重要。支原体污染对这些产品的品质和安全构成严重风险。受污染的生物药品和疫苗可能会对患者造成不利影响、监管问题以及製造商的财务损失。为了满足监管要求并维持产品质量，生物製药和疫苗製造商越来越多地投资先进的支原体检测解决方案。这些解决方案能够快速且准确地检测支原体污染，同时有助于维护生物製药和疫苗生产过程的完整性。

支原体检测市场根据产品类型、应用、技术、最终用途和地区进行分类。

2024年至2032年，仪器产品类型细分市场的市场规模预计将以11.8%的复合年增长率大幅增长。 、准确的支原体检测细胞培养物和生物製药产品中的污染。这些仪器可实现高通量筛选和自动化，进而提高支原体检测实验室的效率和生产力。此外，创新便携式仪器的出现促进了现场测试，进一步缩短了周转时间并实现了污染风险的即时监控。

从技术角度来看，酵素连结免疫吸附测定(ELISA) 领域的支原体检测产业预计到2032 年复合年增长率将达到11.8%。製品中的支原体抗原或抗体。凭藉其高灵敏度和可扩展性，ELISA 还为研究实验室和生物製药生产设施中的常规支原体筛检提供了经济高效的解决方案。

在快速工业化、生物製药研发投资增加以及对产品安全和品质标准意识不断增强的推动下，亚太地区支原体检测行业预计到 2032 年将以 12.3% 的复合年增长率增长。在政府有利措施、基础设施发展和技术进步的推动下，中国、印度和日本等国家的生物製药生产活动激增。此外，大量熟练劳动力和具有成本效益的製造能力的存在将进一步扩大区域市场的扩张。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 细胞培养技术的进步
      • 细胞培养物污染上升
      • 增加研发活动
      • 对快速、准确且经济实惠的支原体检测的需求不断增长
    • 产业陷阱与挑战
      • 检测过程漫长而费力
      • 严格的监管场景
  • 成长潜力分析
  • 技术景观
  • 监管环境
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 竞争定位矩阵
  • 战略展望矩阵

第 5 章：市场估计与预测：按产品类型，2018 年 - 2032 年

  • 主要趋势
  • 仪器
  • 试剂盒和试剂
    • PCR（聚合酶炼式反应）检测
    • 核酸检测试剂盒
    • 污渍
    • 消除套件
    • 标准和控制
    • ELISA（酵素连结免疫吸附测定）试剂盒
    • 其他试剂盒和试剂
  • 服务

第 6 章：市场估计与预测：按技术划分，2018 年 - 2032 年

  • 主要趋势
  • PCR（聚合酶炼式反应）
  • ELISA（酵素连结免疫吸附测定）
  • 微生物培养技术
  • 酵素法
  • 其他技术

第 7 章：市场估计与预测：按应用分类，2018 年 - 2032 年

  • 主要趋势
  • 细胞系测试
  • 病毒检测
  • 生产单元测试结束
  • 其他应用

第 8 章：市场估计与预测：依最终用途，2018 - 2032 年

  • 主要趋势
  • 学术研究机构
  • 细胞库和实验室
  • 合约研究组织
  • 製药和生物技术公司
  • 其他最终用户

第 9 章：市场估计与预测：按地区划分，2018 年 - 2032 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿联酋
    • 中东和非洲其他地区

第 10 章：公司简介

  • Becton, Dickinson, and Company (BD)
  • Bio-Rad Laboratories, Inc.
  • Charles River Laboratories International, Inc.
  • Creative Bioarray
  • Eurofins Scientific
  • InvivoGen
  • Lonza Group AG
  • Merck KGaA
  • Minerva Biolabs GmbH
  • PromoCell GmbH
  • QIAGEN N.V.
  • Sartorius AG
  • Thermo Fisher Scientific Inc.
简介目录
Product Code: 8300

Mycoplasma Testing Market size is expected to grow at over 11.9% CAGR during 2024-2032, driven by increasing prevalence of mycoplasma contamination in cell culture-based research and the strong need for biopharmaceuticals and vaccines. The growing demand for biopharmaceuticals and vaccines is a significant driver propelling the market expansion. Biopharmaceuticals, including monoclonal antibodies, recombinant proteins, and gene therapies, are becoming the cornerstone of modern medicine. As per WHO, in 2021 alone, the global supply of vaccines amounted to 16 billion doses, valued at approximately US$ 141 billion.

As biopharmaceuticals and vaccines are manufactured using complex cell culture processes, ensuring their safety and efficacy has turned paramount. Mycoplasma contamination poses a serious risk to the quality and safety of these products. Contaminated biopharmaceuticals and vaccines can lead to adverse effects on patients, regulatory issues, and financial losses for manufacturers. To meet regulatory requirements and maintain product quality, biopharmaceutical and vaccine manufacturers are increasingly investing in advanced mycoplasma testing solutions. These solutions enable rapid and accurate detection of mycoplasma contamination while helping to safeguard the integrity of biopharmaceutical and vaccine production processes.

The mycoplasma testing market is classified based on product type, application, technique, end-use and region.

The market size from the instruments product type segment is expected to grow substantially at 11.8% CAGR from 2024 to 2032. Advanced instrumentation technologies, such as polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs) offer rapid and accurate detection of mycoplasma contamination in cell cultures and biopharmaceutical products. These instruments enable high-throughput screening and automation, enhancing efficiency and productivity in mycoplasma testing laboratories. Additionally, the advent of innovative portable instruments facilitates on-site testing, further reducing turnaround times and enabling real-time monitoring of contamination risks.

By technique, the mycoplasma testing industry from the enzyme-linked immunosorbent assay (ELISA) segment is poised to record 11.8% CAGR through 2032. ELISA-based assays leverage the specificity of antigen-antibody interactions to detect and quantify mycoplasma antigens or antibodies in biological samples. With its high sensitivity and scalability, ELISA also offers a cost-effective solution for routine mycoplasma screening in research laboratories and biopharmaceutical manufacturing facilities.

Asia Pacific mycoplasma testing industry is set to expand at 12.3% CAGR till 2032, driven by rapid industrialization, increasing investments in biopharmaceutical R&D, and the growing awareness about product safety and quality standards. Countries, such as China, India, and Japan are witnessing a surge in biopharmaceutical manufacturing activities, fueled by favorable government initiatives, infrastructure development, and technological advancements. Moreover, the presence of a large pool of skilled labor and cost-effective manufacturing capabilities will further augment the regional market expansion.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Base estimates & calculations
  • 1.3 Data collection
  • 1.4 Forecast parameters
  • 1.5 Data validation
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Public sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Advancements in cell culture technology
      • 3.2.1.2 Rising cell culture contamination
      • 3.2.1.3 Increasing research and development activities
      • 3.2.1.4 Increasing demand for fast, accurate, and affordable mycoplasma testing
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Long and laborious detection process
      • 3.2.2.2 Stringent regulatory scenario
  • 3.3 Growth potential analysis
  • 3.4 Technological landscape
  • 3.5 Regulatory landscape
  • 3.6 Porter's analysis
    • 3.6.1 Supplier power
    • 3.6.2 Buyer power
    • 3.6.3 Threat of new entrants
    • 3.6.4 Threat of substitutes
    • 3.6.5 Industry rivalry
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Competitive positioning matrix
  • 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product Type, 2018 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Instruments
  • 5.3 Kits and reagents
    • 5.3.1 PCR (Polymerase chain reaction) assays
    • 5.3.2 Nucleic acid detection kits
    • 5.3.3 Stains
    • 5.3.4 Elimination kits
    • 5.3.5 Standards & controls
    • 5.3.6 ELISA (Enzyme-linked immunosorbent assay) kits
    • 5.3.7 Other kits and reagents
  • 5.4 Services

Chapter 6 Market Estimates and Forecast, By Technique, 2018 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 PCR (Polymerase chain reaction)
  • 6.3 ELISA (Enzyme-linked immunosorbent assay)
  • 6.4 Microbial culturing technique
  • 6.5 Enzymatic methods
  • 6.6 Other techniques

Chapter 7 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Cell line testing
  • 7.3 Virus testing
  • 7.4 End of production cells testing
  • 7.5 Other applications

Chapter 8 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Academic research institutes
  • 8.3 Cell banks & laboratories
  • 8.4 Contract research organizations
  • 8.5 Pharmaceutical & biotechnology companies
  • 8.6 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 South Africa
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 Becton, Dickinson, and Company (BD)
  • 10.2 Bio-Rad Laboratories, Inc.
  • 10.3 Charles River Laboratories International, Inc.
  • 10.4 Creative Bioarray
  • 10.5 Eurofins Scientific
  • 10.6 InvivoGen
  • 10.7 Lonza Group AG
  • 10.8 Merck KGaA
  • 10.9 Minerva Biolabs GmbH
  • 10.10 PromoCell GmbH
  • 10.11 QIAGEN N.V.
  • 10.12 Sartorius AG
  • 10.13 Thermo Fisher Scientific Inc.